Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML
Current Treatment Options in Oncology · 2025
DOI: 10.1007/s11864-025-01351-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2025. Verfasst von Gray H Magee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Atrium Health Levine Cancer Institute, 1021 Morehead Medical Drive, LCI Building 2, Charlotte, NC, 28204, USA. Gray.magee@advocatehealth.org. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wake Forest University.
Abstract (Originalsprache)
Opinion statement The integration of next-generation sequencing (NGS) and advanced cytogenetic diagnostics into routine clinical practice is reshaping frontline treatment of acute myeloid leukemia (AML) in both fit and unfit patients. Molecular profiling now enables personalized treatment strategies, particularly for patients harboring mutations in FLT3 , IDH1 , IDH2 , KMT2A , and NPM1 . Small molecule inhibitors, first reserved for relapsed/refractory disease, are increasingly used in the upfront setting. However, universal NGS testing at diagnosis is critical to identify eligible patients for these targeted therapies. In patients lacking actionable mutations, treatment can still be refined using karyotypic abnormalities or high-risk features suggestive of antecedent MDS. In our practice, we continue to use 7 + 3 induction for fit patients, adding midostaurin or quizartinib for FLT3 -mutated AML, or gemtuzumab ozogamicin for core binding factor (CBF) AML expressing CD33. For patients with therapy-related AML or AML with myelodysplasia-related changes, CPX-351 is our standard induction approach. For unfit patients, we generally offer hypomethylating agents with venetoclax. In the presence of IDH1 mutations, we consider azacitidine combined with ivosidenib. If venetoclax is contraindicated or not tolerated, targeted therapies such as gilteritinib, ivosidenib, or enasidenib may be appropriate based on mutation profile. However, we try to identify clinical trials for all our patients at diagnosis. One of the more exciting recent developments is the emergence of menin inhibitors for patients with KMT2A rearrangements or NPM1 mutations. While several agents have received FDA approval or breakthrough status in the relapsed/refractory setting, they are now being actively studied as frontline options with promising results. When feasible, clinical trial enrollment should be considered for newly diagnosed patients with these alterations. As the therapeutic landscape for AML continues to evolve, timely molecular characterization is more essential than ever to optimize outcomes and select the most appropriate frontline strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Atrium Health Levine Cancer Institute, 1021 Morehead Medical Drive, LCI Building 2, Charlotte, NC, 28204, USA. Gray.magee@advocatehealth.org.
- Division of Hematology, Atrium Health Levine Cancer Institute and Wake Forest University School of Medicine, 1021 Morehead Medical Drive, LCI Building 2, Suite 60100, Charlotte, NC, 28204, USA.
Förderung
- Wake Forest University
Zitieren
APA
Magee, G. H., & Grunwald, M. R. (2025). Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-025-01351-3
Vancouver
Magee GH, Grunwald MR. Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML. Current Treatment Options in Oncology. 2025. doi:10.1007/s11864-025-01351-3
BibTeX
@article{Magee2025,
author = {Magee, Gray H and Grunwald, Michael R},
title = {Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML},
journal = {Current Treatment Options in Oncology},
year = {2025},
doi = {10.1007/s11864-025-01351-3}
}
EUVIMED